A systematic review and economic evaluation of statins for the prevention of coronary events
Open accessThe DOI matches its Crossref record; 342 of the 356 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of statins for the primary and secondary prevention of cardiovascular events in adults with, or at risk of, coronary heart disease (CHD). DATA SOURCES: Electronic databases were searched between November 2003 and April 2004. REVIEW METHODS: A review was undertaken to identify and evaluate all literature relating to the clinical and cost effectiveness of statins in the primary and secondary prevention of CHD and cardiovascular disease (CVD) in the UK. A Markov model was developed to explore the costs and health outcomes associated with a lifetime of statin treatment using a UK NHS perspective. RESULTS: Thirty-one randomised studies were identified that compared a statin with placebo or with another statin, and reported clinical outcomes. Meta-analysis of the available data from the placebo-controlled studies indicates that, in patients with, or at risk of, CVD, statin therapy is associated with a reduced relative risk of all cause mortality, cardiovascular mortality, CHD mortality and fatal myocardial infarction (MI), but not of fatal stroke. It is also associated with a reduced relative risk of morbidity [non-fatal stroke, non-fatal MI, transient ischaemic attack (TIA), unstable angina] and of coronary revascularisation. It is hardly possible, on the evidence available from the placebo-controlled trials, to differentiate between the clinical efficacy of atorvastatin, fluvastatin, pravastatin and simvastatin. However, there is some evidence from direct comparisons between statins to suggest that atorvastatin may be more effective than pravastatin in patients with symptomatic CHD. There is limited evidence for the effectiveness of statins in different subgroups. Statins are generally considered to be well tolerated and to have a good safety profile. This view is generally supported both by the evidence of the trials included in this review and by postmarketing surveillance data. Increases in creatine kinase and myopathy have been reported, but rhabdomyolysis and hepatotoxicity are rare. However, some patients may receive lipid-lowering therapy for as long as 50 years, and long-term safety over such a timespan remains unknown. In secondary prevention of CHD, the incremental cost-effectiveness ratios (ICERs) increase with age varying between pound 10,000 and pound 17,000 per quality adjusted life year (QALY) for ages 45 and 85 respectively. Sensitivity analyses show these results are robust. In primary prevention of CHD there is substantial variation in ICERs by age and risk. The average ICERs weighted by risk range from pound 20,000 to pound 27,500 for men and from pound 21,000 to pound 57,000 for women. The results are sensitive to the cost of statins, discount rates and the modelling time frame. In the CVD analyses, which take into account the benefits of statins on reductions in stroke and TIA events, the average ICER weighted by risk level remains below pound 20,000 at CHD risk levels down to 0.5%. Limitations of the analyses include the requirement to extrapolate well beyond the timeframe of the trial period, and to extrapolate effectiveness results from higher risk primary prevention populations to the treatment of populations at much lower risk. Consequently, the results for the lower age bands and lower risks are subject to greater uncertainty and need to be treated with caution. CONCLUSIONS: There is evidence to suggest that statin therapy is associated with a statistically significant reduction in the risk of primary and secondary cardiovascular events. As the confidence intervals for each outcome in each prevention category overlap, it is not possible to differentiate, in terms of relative risk, between the effectiveness of statins in primary and secondary prevention. However, the absolute risk of CHD death/non-fatal MI is higher, and the number needed to treat to avoid such an event is consequently lower, in secondary than in primary prevention. The generalisability of these results is limited by the exclusion, in some studies, of patients who were hypersensitive to, intolerant of, or known to be unresponsive to, statins, or who were not adequately compliant with study medication during a placebo run-in phase. Consequently, the treatment effect may be reduced when statins are used in an unselected population. The results of the economic modelling show that statin therapy in secondary prevention is likely to be considered cost-effective. In primary prevention, the cost-effectiveness ratios are dependent on the level of CHD risk and age, but the results for the CVD analyses offer support for the more aggressive treatment recommendation issued by recent guidelines in UK. Evidence on clinical endpoints for rosuvastatin is awaited from on-going trials. The potential targeting of statins at low-risk populations is however associated with major uncertainties, particularly the likely uptake and long-term compliance to lifelong medica
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce. 7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce.7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lowering blood cholesterol levels using statins 10,11,23-25 and improving blood pressure control are also cost effective. 26,27”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Part of this paper’s reference list could not be split into single entries.
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
The National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
(2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00001 · Cited by 3,027
Research works printed but not linked: 20
- Sproston K, Primatesta P. Health Survey for England 2003. Vol. 1. Cardiovascular disease. London: Department of Health; 2004.
- Gibbs RGJ, Newson R, Lawrenson R, Greenhalgh RM, Davies AH. Diagnosis and initial management of stroke and transient ischemic attack across UK health regions from 1992 to 1996: experience of a national primary care database. Stroke 2001;32:1085-90.
- Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid- lowering therapies on stroke prevention: a meta- analysis of randomized trials. Arch Intern Med 2003;163:669-76.
- National Statistics. Mortality statistics: cause. Review of the Registrar General on deaths by cause, sex and age, in England and Wales, 2001. DH2 No. 28. London: Office for National Statistics; 2003. References
- Hackett ML, Duncan JR, Anderson CS, Broad JB, Bonita R. Health-related quality of life among long-term survivors of stroke: results from the Auckland Stroke Study, 1991-1992. Stroke 2000; 31:440-7.
- Goyder E, McBeath S, Sims A, Ashwell S, Sherry R. Quantifying the gap between policy and practice in cardiovascular risk reduction. A review of the evidence from recent cardiovascular and diabetes audits in the UK. Oxford: South East Public Health Observatory and Trent Public Health Observatory; 2003.
- Dr Foster's case notes: Prescribing of lipid regulating drugs and admissions for myocardial infarction in England. BMJ 2004;329:645.
- Committee on Safety of Medicines. Statins and cytochrome P450 interactions. Current Problems in Pharmacovigilance 2004;30:1-2.
- Cranney A, Tugwell P, Wells G, Guyatt G. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002;23:497-507.
- Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81.
- Voss S, Quail D, Dawson A, Backstrom T, Aguas F, Erenus M, et al. A randomised, double-blind trial comparing raloxifene HCI and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 2002;109:874-85.
- McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79.
- Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharmaceutical Journal 2004;272:23-6.
- Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793-802.
- Review Manager (RevMan). URL: http://www.cc-ims.net/RevMan. Accessed September 2000.
- Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
- Olsson AG, Eriksson M, Johnson O, Kjellstrom T, Lanke J, Larsen ML, et al. 3-Study Investigators. A 52-week, multicenter, randomized, parallel- group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the Treat-to-Target (3T) study. Clin Ther 2003;25:119-38.
- Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577-81.
- Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
- Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeitat K, et al. The effect of simvastatin on progression of coronary artery disease. The multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-34.
Cited by
Items 301–400 of 602
Eussen, S. R. B. M., Feenstra, T., Toxopeus, I. B., Hoekstra, J., Klungel, O. H., Verhagen, H., van Kranen, H. J., & Rompelberg, C. J. M. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.081 · Cited by 18
“(2007)), and were found to be cost-effective for high risk patients (Franco et al., 2005; Ward et al., 2007).”
BackgroundGordon, W. J., Polansky, J. M., Boscardin, W. J., Fung, K. Z., & Steinman, M. A. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1454-2 · Cited by 18
Evaluation of a diabetes care program using the effective coverage framework
Lopez-Lopez, E., Gutierrez-Soria, D., & Idrovo, Á. J. (2012) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzs056 · Cited by 18
Deidda, M., Coll‐Planas, L., Giné‐Garriga, M., Guerra-Balic, M., Figuls, M. R. I., Tully, M. A., Caserotti, P., Rothenbacher, D., Salvà, A., Kee, F., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-022266 · Cited by 18
Jansen, J. P., Gaugris, S., Choy, E., Östör, A. J. K., Nash, J. T., & Stam, W. B. (2010) · PharmacoEconomics · doi:10.2165/11314690-000000000-00000 · Cited by 18
Monahan, M., Jowett, S. M., Lovibond, K., Gill, P. S., Godwin, M. S., Greenfield, S., Hanley, J., Hobbs, R. F., Martin, U., Mant, J., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.10244 · Cited by 18
Jones, L. K., East, C. A., Ganda, O. P., & Gionfriddo, M. R. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037530 · Cited by 17
“83 These extreme estimates may be the result of confounding or imbalances between the adherent and nonadherent groups.”
Mickenautsch, S., & Yengopal, V. (2012) · Journal of minimum intervention in dentistry · Cited by 17
Chan, J. C. N., Chan, S. P., Deerochanawong, C., Go, R. T., Lee, K., Ronald, C. W., Pan, C., Sheu, W. H., & Barter, P. J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.05.034 · Cited by 17
“However, in a meta-analysis of 31 randomized trials, economic modelling supported the costeffectiveness of statin therapy, both as primary and secondary prevention, dependent on the level of CHD risk and age [102].”
BackgroundBrice, A., Price, A. I., & Burls, A. (2015) · Digital Health · doi:10.1177/2055207615617854 · Cited by 17
Estcourt, C. S., Howarth, A., Copas, A. J., Low, N. N., Mapp, F., Owusu, M. W., Flowers, P., Roberts, T. E., Mercer, C. H., Wayal, S., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034806 · Cited by 17
O’Flaherty, M., Lloyd‐Williams, F., Capewell, S., Boland, A., Maden, M., Collins, B., Bandosz, P., Hyseni, L., & Kypridemos, C. (2021) · Health Technology Assessment · doi:10.3310/hta25350 · Cited by 17
Šović, N., Pająk, A., Jankowski, P., Duenas, A., Kawecka−Jaszcz, K., Wolfshaut–Wolak, R., Stepaniak, U., & Kawalec, P. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0157 · Cited by 17
“To determine distribution to specific CHD events, in the absence of published Polish data, age- and gender-dependent incidence rates of primary events and transition probabilities of secondary events were derived from British registries [7].”
Bai, Y., Ye, M., Cao, H., Ma, X., Xu, Y., & Wu, B. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2268-1 · Cited by 17
Múñoz, Ó., Peña, Á. A. G., Fernández, D., Higuera, A. M., Ruiz, Á. J., Aschner, P. J., Toro, J. M., Arteaga, J. M., Merchán, A., Vallejo, G. S., et al. (2015) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2015.02.001 · Cited by 17
Wallach‐Kildemoes, H., Diderichsen, F., Krasnik, A., Lange, T., & Andersen, M. T. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-610 · Cited by 17
“There is an ongoing debate about the high-risk strategy [14,27-29], encompassing allocation of scarce health care resources [28] and “The strategy of preventive medicine”, by Geoffrey Rose [30], i.”
BackgroundZimovetz, E. A., Wilson, K., Samuel, M., & Beard, S. M. (2010) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2010.01439.x · Cited by 17
Tebruegge, M., Salo, E., Ritz, N., Kampmann, B., & On behalf of the Paediatric Tuberculosis Network European Trialsgroup (ptbnet) (2012) · Thorax · doi:10.1136/thoraxjnl-2012-202824 · Cited by 17
Monitoring ocular hypertension, how much and how often? A cost-effectiveness perspective
Hernández, R. A., Burr, J. M., Vale, L. D., Azuara‐Blanco, A., Cook, J. A., Banister, K., Tuulonen, A., & Ryan, M. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-306757 · Cited by 17
Ara, R., Pandor, A., Tumur, I., Paisley, S., Duenas, A., WILLIAMS, R., WILKINSON, A., Durrington, P. N., & Chilcott, J. B. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.002 · Cited by 17
Self-citationLahsaee, S., Corkery, D., Anthes, L. E., Holly, A. C., & Dellaire, G. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.12.013 · Cited by 17
Harland, J. I. (2009) · Nutrition Bulletin · doi:10.1111/j.1467-3010.2009.01756.x · Cited by 17
Statintherapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases
Feher, A., Pusch, G., Koltai, K., Tibold, A., Gasztonyi, B., Szapáry, L. B., & Fehér, G. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.08.012 · Cited by 17
Future Screening for Incipient Alzheimer’s Disease – The Influence of Prevalence on Test Performance
Mattsson, N., & Zetterberg, H. (2009) · European Neurology · doi:10.1159/000228591 · Cited by 17
Liew, D., Park, H.-J., & Ko, S.-K. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.10.015 · Cited by 17
Detecting lung infections in breathprints: empty promise or next generation diagnosis of infections
Haick, H., & Cohen‐Kaminsky, S. (2014) · European Respiratory Journal · doi:10.1183/09031936.00183714 · Cited by 17
Dunkley, A. J., Tyrer, F., Spong, R., Gray, L. J., Gillett, M., Doherty, Y., Martin-Stacey, L., Patel, N., Yates, T. E., Bhaumik, S., et al. (2017) · Programme Grants for Applied Research · doi:10.3310/pgfar05110 · Cited by 16
Lv, X., Qi, J., Zhou, M., Shi, B., Cai, C., Tang, Y., Pan, T., & Han, Y. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102944 · Cited by 16
Gaikwad, S., Jadhav, V., Gurav, A. N., Shete, A., & Dearda, H. M. (2013) · Journal of Periodontal & Implant Science · doi:10.5051/jpis.2013.43.1.37 · Cited by 16
Gastrointestinal Disturbances in the Elderly
Baker, N. R., & Blakely, K. K. (2017) · Nursing Clinics of North America · doi:10.1016/j.cnur.2017.04.001 · Cited by 16
The Value of Atorvastatin Over the Product Life Cycle in the United States
Grabner, M., Johnson, W. R., Abdulhalim, A. M., Kuznik, A., & Mullins, C. D. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.08.014 · Cited by 16
Marino, P., Siani, C., Roche, H. H., Protière, C., Fumoleau, P., Spielmann, M., Martin, A., Viens, P., & Corroller, A. L. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp561 · Cited by 16
Wei, C.-Y., Quek, R. G. W., Villa, G., Gandra, S. R., Forbes, C. A., Ryder, S., Armstrong, N., Deshpande, S., Duffy, S., Kleijnen, J., et al. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0464-2 · Cited by 16
The patterns of antihypertensive drug prescription by cardiologists in Kerman province of Iran, 2006
Sepehri, G., Talebizadeh, N., Mirzazadeh, A., & Mohsenbeigi, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1521 · Cited by 16
A methodological framework for developing the structure of Public Health economic models
Squires, H. (2014) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 16
Vargas, C., Espinoza, M., Giglio, A., & Soza, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141660 · Cited by 15
Rachamin, Y., Meier, R., Rosemann, T. J., Langenegger, S. J., & Markun, S. (2020) · Swiss Medical Weekly · doi:10.4414/smw.2020.20244 · Cited by 15
Secondary prevention of ischaemic cardiac events.
Skinner, J. S., & Cooper, A. M. (2011) · Europe PMC (PubMed Central) · Cited by 15
Paszel, A., Rubiś, B., Bednarczyk–Cwynar, B., Zaprutko, L., Kaczmarek, M., Hofmann, J., & Rybczyńska, M. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70714-9 · Cited by 15
Sánchez-Medina, J., González‐Ramella, O., & Gallegos‐Castorena, S. (2010) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181d321b3 · Cited by 15
Statins: Pharmacokinetics, Pharmacodynamics and Cost-Effectiveness Analysis
Ricci, G., Ciccone, M. M., Giordano, P., & Cortese, F. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180706144824 · Cited by 15
Overview of methods in economic analyses of behavioral interventions to promote oral health
O’Connell, J., & Griffin, S. C. (2011) · Journal of Public Health Dentistry · doi:10.1111/j.1752-7325.2011.00236.x · Cited by 15
Sorensen, S. V., Frick, K. D., Wade, A., Simko, R. J., & Burge, R. T. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.04.015 · Cited by 15
Ara, R., & Brazier, J. E. (2009) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 15
Self-citationDieterich, D. T., Asselah, T., Guyader, D., Berg, T., Schuchmann, M., Mauss, S., Ratziu, V., Ferenci, P., Larrey, D. G., Maieron, A., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02497-13 · Cited by 14
Combined structure–function analysis in glaucoma screening
Karvonen, E., Stoor, K., Luodonpää, M., Hägg, P. O., Leiviskä, I. L., Liinamaa, J., Tuulonen, A., & Saarela, V. O. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-319178 · Cited by 14
Campone, M., Yang, H., Faust, E., Kageleiry, A., Signorovitch, J., Zhang, J., & Gao, H. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.959589 · Cited by 14
Statin Utilization in Nursing Home Patients after Cardiac Hospitalization
Parikh, S., Shrank, W. H., Mogun, H., & Choudhry, N. K. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1473-z · Cited by 14
Should We Modify Our Indications After the EVAR-2 Trial Conclusions?
Sobocinski, J., Maurel, B., Delsart, P., D’Elia, P., Guillou, M., Maioli, F., Perot, C., Bianchini, A., Azzaoui, R., Mounier‐Véhier, C., et al. (2011) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2010.08.010 · Cited by 14
Man, F., Chen, C. X., Lau, Y., & Chan, K. (2016) · Hong Kong Medical Journal · doi:10.12809/hkmj154667 · Cited by 14
Cost-Effective Hearing Conservation: Regulatory and Research Priorities
Dobie, R. A. (2017) · Ear and Hearing · doi:10.1097/aud.0000000000000523 · Cited by 14
Fluvastatin-induced alterations of skeletal muscle function in hypercholesterolaemic rats
Fűzi, M., Palicz, Z., Vincze, J., Cseri, J., Szombathy, Z., Kovács, I., Oláh, A. V., Szentesi, P., Kertai, P., Paragh, G., et al. (2011) · Journal of Muscle Research and Cell Motility · doi:10.1007/s10974-011-9272-7 · Cited by 13
Prostate Cancer Prevention: Concepts and Clinical Trials
Hamilton, Z. A., & Parsons, J. K. (2016) · Current Urology Reports · doi:10.1007/s11934-016-0587-1 · Cited by 13
Jones, F. J. S., Sanches, P. R., Smith, J. R., Zafar, S. F., Hernández–Díaz, S., Blacker, D., Hsu, J., Schwamm, L. H., Westover, M. B., & Moura, L. M. V. R. (2021) · Stroke · doi:10.1161/strokeaha.120.033299 · Cited by 13
Pravastatin for lowering lipids
Adams, S. P., Alaeiilkhchi, N., Tasnim, S., & Wright, J. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013673.pub2 · Cited by 13
Bays, A. M., & Pierson, D. J. (2012) · Respiratory Care · doi:10.4187/respcare.01443 · Cited by 13
Zomer, E., Leach, R. J., Trimmer, C., Lobstein, T., Stephen Morris, A., James, W. P. T., & Finer, N. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12792 · Cited by 13
“nary heart disease (CHD), CHD death, transient ischaemic attack, stroke and stroke death, according to age and sex, as per distributions in the ScHARR model.(8) With each annual cycle, annual changes in modifiable risk factors such as systolic blood pressure, total and HDL”
InfluentialShah, K. K., Willson, M. L., Agresta, B., & Morton, R. L. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00364-0 · Cited by 13
Mashamba-Thompson, T. P., Drain, P. K., & Sartorius, B. K. D. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011155 · Cited by 13
Lee, J., Lee, S. H., Kim, H., Lee, S., Cho, J., Lee, H., Yim, H. W., Yoon, K., Kim, H., & Kim, J. H. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13271 · Cited by 13
Atella, V., & Kopinska, J. A. (2013) · International Journal of Public Health · doi:10.1007/s00038-013-0528-4 · Cited by 13
Yu, J., Chan, K., Kurin, M., Pasetka, M., Kiss, A., Sridhar, S. S., & Warner, E. (2015) · The Breast Journal · doi:10.1111/tbj.12501 · Cited by 12
Taylor, F. C., & Ebrahim, S. B. J. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.2434 · Cited by 12
Stollenwerk, B., Gerber, A., Lauterbach, K. W., & Siebert, U. (2009) · Medical Decision Making · doi:10.1177/0272989x09331810 · Cited by 12
“During their lifetime, subjects in states h+ and h− may develop CAD.”
BackgroundInfluentialEmerging Targets for the Treatment of Dyslipidemia
Tavridou, A., Ragia, G., & Manolopoulos, V. G. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794927757 · Cited by 12
“Unfortunately, not all patients treated with statins achieve target LDL-cholesterol levels partly because of limitations such as intolerance, dose-dependent hepatotoxicity and myotoxicity [18, 19], and cost-effectiveness [20].”
BackgroundBejarano, J. M. L., Galve, E., Royo‐Bordonada, M. Á., Ezquerra, E. A., Armario, P., Cuixart, C. B., Camafort, M., Cordero, A., Galán, A. M., Morató, T. M., et al. (2014) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2014.09.002 · Cited by 12
“Economic assessment shows that statins are cost-effective compared with nonactive treatment in the secondary prevention of CVD and in primary prevention in high-risk patients, but their cost-effectiveness is less clear as risk decreases.(14) Thus, it is important to determine the economic impact of the drastic change…”
BackgroundSi, S., Moss, J. R., Karnon, J. D., & Stocks, N. P. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207110 · Cited by 12
Optional copayments on anti-cancer drugs
van de Vooren, K., Curto, A., & Garattini, L. (2013) · BMJ · doi:10.1136/bmj.f349 · Cited by 12
The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients
Degreef, L. E., Opdam, F. L., Teepe‐Twiss, I. M., Jukema, J. W., Guchelaar, H., & Tamsma, J. T. (2010) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.03.015 · Cited by 12
Primary prevention of cardiovascular diseases: a cost study in family practices
de Bekker-Grob, E. W., van Dulmen, S., van den Berg, M., Verheij, R. A., & Slobbe, L. (2011) · BMC Family Practice · doi:10.1186/1471-2296-12-69 · Cited by 12
“prescribing of blood-pressure-lowering drugs, or lifestyle counselling) aimed at a determinant of cardiovascular disease for people without CVD) [5-9].”
BackgroundBreeze, P. R., Thomas, C., Squires, H., Brennan, A., Greaves, C. J., Diggle, P. J., Brunner, E. J., Tabák, Á. G., Preston, L., & Chilcott, J. B. (2015) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 12
Bayesian Modelling for Binary Outcomes in the Regression Discontinuity Design
Geneletti, S., Ricciardi, F., O’Keeffe, A. G., & Baio, G. (2019) · Journal of the Royal Statistical Society Series A (Statistics in Society) · doi:10.1111/rssa.12440 · Cited by 12
Sauvaget, A., Lagalice, L., Schirr-Bonnans, S., Volteau, C., Péré, M., Dert, C., Bonnin-Rivalland, A., Tessier, F., Lepage, A., Tostivint, A., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033376 · Cited by 12
The timing of adoption of positron emission tomography: a real options approach
Pertile, P., Torri, E., Flor, L., & Tardivo, S. (2008) · Health Care Management Science · doi:10.1007/s10729-008-9085-4 · Cited by 12
Statins for Cardiovascular Prevention According to Different Strategies: A Cost Analysis
Ito, M. K., Nanchen, D., Rodondi, N., Paccaud, F., Waeber, G., Vollenweider, P., & Marques-Vidal, P. (2011) · American Journal Cardiovascular Drugs · doi:10.2165/11586760-000000000-00000 · Cited by 11
“In a previous study,[11] we calculated the number of individuals needed to treat to prevent one CHD event or one CHD death according to three different guidelines for statin use in the primary prevention of CHD.”
BackgroundInfluentialGuthrie, B., Rogers, G., Livingstone, S. J., Morales, D. R., Donnan, P. T., Davis, S., Youn, J.-H., Hainsworth, R., Thompson, A., & Payne, K. (2024) · Health and Social Care Delivery Research · doi:10.3310/kltr7714 · Cited by 11
Risk stratification and pattern of cardiotoxicity in pediatric Ewing sarcoma
Moussa, E. A. H., Zamzam, M., Kamel, A., Salah, Z., Attia, I., Gaber, L., Soliman, R., & Ezzat, S. (2017) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2016.12.001 · Cited by 11
Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease
Suh, D., Griggs, S. K., Henderson, E. R., Lee, S.-M., & Park, T. (2017) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2018.1407246 · Cited by 11
“One report in this journal found the cost-effectiveness of statins, compared with other standard treatments, was dependent on the level of CHD, age, and gender in primary prevention while the statin therapy was likely to be cost-effective in secondary prevention [71].”
BackgroundBlood pressure telemonitoring and remote counseling in uncontrolled hypertension
Васильевич, И. М., Жукова, О. В., Звартау, Н. Э., & Конради, А. О. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.01.200590 · Cited by 11
“QALY для различных неблагоприятных событий хсН 0,69 [39] иМ 0,76 (0,5–0,87) [40] ОНМк 0,63 (0,26–0,92) [41]”
Préservation de la fertilité dans le cancer du sein : où en est-on en 2014 ?
Comtet, M., Sonigo, C., Valdelièvre, C., Sermondade, N., Sifer, C., & Grynberg, M. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.01.008 · Cited by 11
Feenstra, T., van Baal, P. H. M., der Bruggen, M. A. M. J.-V., Hoogenveen, R. T., Kommer, G., & Baan, C. A. (2011) · Cost Effectiveness and Resource Allocation · doi:10.1186/1478-7547-9-14 · Cited by 11
“Economic evaluations for a range of lifestyle and drug interventions targeting diabetes patients,[9,10] or the general population [11-15] have been published in recent years.”
BackgroundAssociation of alprazolam with major cardiovascular events in patients with hypertension
Yeh, C., Tsai, M., Teng, Y., Ku, M., Huang, J., Wang, B.-Y., Tai, C., Kornelius, E., & Ho, S. (2019) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13254 · Cited by 11
Camejo, R. R., McGrath, C., Herings, R. M. C., Meerding, W., & Rutten, F. (2011) · Value in Health · doi:10.1016/j.jval.2011.08.1736 · Cited by 11
Amirsadri, M., & Sedighi, M. (2017) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.202453 · Cited by 11
Phospholipid biomarkers of coronary heart disease
Morita, S. (2024) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-024-00344-y · Cited by 10
Bejarano, J. M. L., Galve, E., Royo‐Bordonada, M. Á., Ezquerra, E. A., Armario, P., Cuixart, C. B., Camafort, M., Cordero, A., Galán, A. M., Morató, T. M., et al. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.05.008 · Cited by 10
“Economic assessment shows that statins are cost-effective compared with nonactive treatment in the secondary prevention of CVD and in primary prevention in high-risk patients, but their cost-effectiveness is less clear as risk decreases.(14) Thus, it is important to determine the economic impact of the drastic change…”
BackgroundOhsfeldt, R. L., OLSSON, A. G., Jensen, M. M., Gandhi, S. K., & Paulsson, T. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2011.627073 · Cited by 10
“Utility weights for each CVD event were based on estimates reported by Ward et al.(16) and Scuffham and Kosa(24), as noted in Table 2.”
MethodInclusion of the birth cohort dimension improved description and explanation of trends in statin use
Bijlsma, M. J., Hak, E., Bos, J., den Berg, L. T. W. D. J., & Janssen, F. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.05.009 · Cited by 10
“This is considered accurate because statin continuance within 1 year is high [23].”
Lee, S. I., & Narendran, P. (2014) · BMJ Case Reports · doi:10.1136/bcr-2014-205278 · Cited by 10
Sheppard, J. P., Mellor, R. M., Bailey, S. M., Barton, P. M., Boyal, A., Greenfield, S., Jowett, S. M., Mant, J., Quinn, T., Singh, S., et al. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001430 · Cited by 10
Mitigating GI Risks Associated with the Use of NSAIDs: Table 1
Momeni, M., & Katz, J. D. (2013) · Pain Medicine · doi:10.1111/pme.12225 · Cited by 10
Jabbari, A., Jafari, A., Hadian, M., & Ghasemi, M. (2020) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_578_18 · Cited by 10
A systematic review and economic evaluation of statins for the prevention of coronary events
(2007) · Clinical Governance An International Journal · doi:10.1108/cgij.2007.24812dae.001 · Cited by 10
Shi, Y.-F., Chi, J., Tang, W., Xu, F., Liu, L.-B., Ji, Z., Lv, H., & Guo, H. (2013) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.bqicc703 · Cited by 10
“Thus, the results of this study suggest that rosuvastatin may reduce the risk of CHD in patients with hyperhomocysteinemia, by reducing the abnormal migration of VSMCs and the expression and activation of MMP-2 in VSMCs induced by hyperhomocysteinemia.”
BackgroundInfluentialStarting and staying on preventive medication for cardiovascular disease
Gale, N. K., Marshall, T. P., & Bramley, G. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328356dae5 · Cited by 10
Dirichlet process mixture models for regression discontinuity designs
Ricciardi, F., Liverani, S., & Baio, G. (2022) · Statistical Methods in Medical Research · doi:10.1177/09622802221129044 · Cited by 9
“ge of risk scores. Prior specications are dened as follows 0a= 0b+ ; 0b˘N(3:7;˙2 b = 0:25); 1l˘N(0;˙2 l = 2); ˙˘Uniform(0;5): To encode in the model some available information from the literature (Ward et al., 2007) about the eect of statins in lowering cholesterol levels, we specify the prior distribution of in order…”
BackgroundMethodSubgroup Economic Evaluation of Radiotherapy for Breast Cancer After Mastectomy
Wan, X., Peng, L., Ma, J., Chen, G., & Li, Y. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.007 · Cited by 9
Salisbury, C., O’Cathain, A., Thomas, C., Edwards, L., Montgomery, A. A., Hollinghurst, S. P., Large, S., Nicholl, J. P., Pope, C. J., Rogers, A. E., et al. (2017) · Programme Grants for Applied Research · doi:10.3310/pgfar05010 · Cited by 9
Syed, M. A., Talbot-Smith, A., & Gemmell, I. (2012) · Journal of Epidemiology and Global Health · doi:10.1016/j.jegh.2012.07.002 · Cited by 9
“42 [ 18 ] , r u = 0 .”
InfluentialStrony, J. T., Hoffman, R., Hanson, M. E., & Veltri, E. P. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.12.008 · Cited by 9
Metadata
- Authors
- Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N.
- Affiliations
- University of Sheffield (GB)
- University of Southampton (GB)
- Royal Hallamshire Hospital (GB)
- Venue
- Health Technology Assessment
- Published
- 2007-04
- Volume
- 11
- Issue
- 14
- Pages
- 1-160, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2048859524
- Cited by
- 556
- References
- 356
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 10 · 2021: 16 · 2020: 25 · 2019: 21 · 2018: 20 · 2017: 34 · 2016: 39 · 2015: 54 · 2014: 45 · 2013: 46 · 2012: 58
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Health Technology Assessment programme (03/30/01)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- statins, coronary artery disease, cardiovascular disease prevention, primary prevention, secondary prevention, cost-effectiveness, cardiovascular mortality, myocardial infarction, stroke, statin safety, rhabdomyolysis, hepatotoxicity, atorvastatin, pravastatin, simvastatin, fluvastatin, Markov model, quality-adjusted life years
- MeSH terms
- Bayes Theorem, Coronary Disease, Cost-Benefit Analysis, Female, Humans, Male, Quality of Life, Meta-Analysis as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.